4546

Small Molecules as PPAR-DELTA Antagonist for Treatment of Metabolic Disorders

Goldblum Amiram, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research

Categories:

Life sciences and Biotechnology

Technology Keywords:

Drug Development, PPARD, Obesity, Glycogen Preserving, Lipid Metabolism, Wound Healing

Development Stage:

In silico, Identification of lead molecules, in vitro  

Application

  • PPAR agonists are drugs acting upon the peroxisome proliferator-activated receptors. They are used for the treatment of symptoms of the metabolic syndrome, mainly for lowering triglycerides and blood sugar, with FDA approved drugs

Our Innovation

Novel, effective and potentially safer set of low nano-molar PPARD

  • Based on a novel algorithm applied for identifying highly selective PPARD agonists with proven activity (a dozen in the low nano-molar range).
  • Highly specific and effective treatment as anti-obesity drugs and preventing diabetes
  • Safer molecules due to their specificity to PPARD, not affecting PPARA and PPARG

Technology

PPARδ agonists have been demonstrated to act as exercise mimics by preserving glycogen and producing energy from lipids. Animal studies demonstrated increased physiological endurance, while human studies have shown increasing HDL and reducing triglycerides. The favorable effects include reducing weight gain, increasing skeletal muscle metabolic rate and endurance, improving insulin sensitivity and cardiovascular function and suppressing atherogenic inflammation.

The Opportunity

  • Obesity and Type II Diabetes are characteristic pathologies of the metabolic syndrome and have reached epidemic proportions in recent years. They are associated with an increased risk of cardiovascular disease and stroke.  

 

Contact for more information:

Mel Larrosa
VP Business Development Healthcare
+972-2-6586692
Contact ME:
Image CAPTCHA